

## SUPPLEMENTAL MATERIAL

### Supplementary Methods

#### *Panel membership and workflow*

DCM gene curation activities were carried out by an international, multi-site Panel of individuals with expertise in laboratory science, molecular diagnostics, research, and/or clinical care in idiopathic DCM. The Panel, termed “The DCM Gene Curation Expert Panel,” a sub-working group of the ClinGen Cardiovascular Clinical Domain Working Group, was composed of 34 individuals from over 20 institutions representing 7 countries (United States, Canada, Netherlands, Australia, United Kingdom, Switzerland, and Italy). Using the ClinGen standard operating procedure (SOP) version 7 (<https://clinicalgenome.org/docs/summary-of-updates-to-the-clingen-gene-clinical-validity-curation-sop-version-7/>), curators scored available evidence and prepared a presentation for full Panel review, discussion, and approval during a biweekly conference call between September 2019 and October 2020 to establish a final classification. Curated data was entered into a web interface, the Gene Curation Interface (GCI), to organize and record evaluated evidence.

#### *Development of the DCM gene list*

To develop a comprehensive list of genes thought to have a role in the development of DCM in humans, a comprehensive search was conducted in three National Center for Biotechnology Information database resources in October 2017: Gene (<https://www.ncbi.nlm.nih.gov/gene>), Online Mendelian Inheritance in Man (OMIM)<sup>1</sup> (<https://www.ncbi.nlm.nih.gov/omim>), and GenBank<sup>2</sup> (<https://www.ncbi.nlm.nih.gov/genbank/>). Starting with Gene, the search terms “dilated cardiomyopathy” OR “cardiomyopathy, dilated” were applied and limited to Homo Sapiens to identify 199 genes. A subsequent search in OMIM

and GenBank using the same search terms, limiting to Animals and Genomic DNA/RNA as the molecule type, identified a list of 204 genes. This initial list was further expanded when adding additional genes not identified in the database query from an expansive DCM gene list that had been previously published<sup>3</sup>, which added 63 genes. The full initial list included 267 genes.

Each gene was then manually evaluated by performing a PubMed search of the “[GENE]” AND “dilated cardiomyopathy” in addition to “[GENE]” AND “cardiomyopathy, dilated” to identify relevant publications proposing a role in the development of idiopathic DCM in humans (May 2018). Genes were removed for the following reasons: those specified as possible candidate genes without supporting animal or human genetic evidence; those that did not have published evidence in human idiopathic DCM; those described as primarily part of a syndrome; and those primarily observed in other non-DCM cardiovascular diseases. Following the application of these criteria, 56 genes remained.

Genes implicated in more than one disease underwent pre-curation to confirm the DCM disease entity and mode of inheritance for each gene curated (<https://clinicalgenome.org/working-groups/lumping-and-splitting/>). Pre-curations were performed to identify the disease entity and mode of inheritance. Pre-curations were shared with the Panel for review prior to formal preparation and scoring of evidence to assign a gene-disease validity classification. During this process, five genes were removed from the curation schedule due to syndromic disease entity (*SDHA*), lack of sufficient evidence specific to the DCM phenotype as defined for this curation effort (*DSC2*, *GATA4*, *GATA6*), or a different cardiomyopathy sub-type as the primary disease entity without a clear assertion for an isolated DCM phenotype in a single gene-disease relationship (*ALPK3*). The remaining 51 genes represent the final gene list (June 2019) (Figure S1).

Five of the genes on the final list were identified as predicted to be classified as definitive (*BAG3*, *LMNA*, *MYH7*, *TNNT2*, and *TTN*) and therefore underwent an expedited curation, requiring the review and approval of two Panel members of the evidence review in an offline mechanism, followed by review and approval of the evidence summary by the full Panel prior to publishing. In addition, two genes had been recently curated by the Hypertrophic Cardiomyopathy Gene Curation Expert Panel (HCM GCEP) for an applicable disease entity, intrinsic cardiomyopathy (MONDO:0000591), and mode of inheritance prior to the DCM gene curation project (*PLN*, <https://search.clinicalgenome.org/kb/gene-validity/8772>; *ACTN2* <https://search.clinicalgenome.org/kb/gene-validity/8772>)<sup>4</sup>. The other 44 genes underwent the standard curation process.

#### *Curation of Published Evidence*


Evaluation of genetic evidence included publications presenting clinical data for patients, families, and large cohorts that could be consider for scoring of individual variants, segregation in pedigrees, and case-control analyses. A minor allele frequency (MAF) cut-off for the maximum credible frequency to have a pathogenic effect was calculated using an allele frequency calculator which integrates disease prevalence, mode of inheritance, genetic and allelic heterogeneity, and penetrance (<https://www.cardiodb.org/allelefrequencyapp/>).<sup>5</sup> We sought to produce a conservative estimate consistent with Mendelian, autosomal dominant disease, occurring at a prevalence 1/250 individuals in the population<sup>6</sup>. While reduced penetrance is commonly observed in DCM, penetrance estimates are not widely available. Further, the penetrance of the genes included in the curation list are anticipated to vary widely, therefore, estimates of 20-40% penetrance were considered. DCM is also highly heterogeneous, with no single variant causing more than 1-2% of DCM cases. Taking these values into consideration, a

maximum credible population allele frequency of 0.0001 was generated, consistent with the clinical standard<sup>7</sup> for monogenic DCM. Variants with a MAF <0.0001 were scored in the curation of genetic evidence.

Experimental evidence was assessed by category (expression data, functional alterations, model systems, and rescue). Expression evidence prioritized studies of human cardiomyocytes or animal models as an alternative when human models were not available. Model systems assessing the disruption to the gene in consideration demonstrated a phenotype suggestive of DCM, and rescue models using cell-culture or non-human animal models with DCM could be rescued by restoring wild-type gene product. Experimental data only evaluating rare variants with some evidence of impact were scored.

Genes with a score reaching a strong classification that demonstrated replication over time in the literature, as defined by at least three years since original publication and at least two independent supporting publications, were classified as definitive. Limited evidence genes lack substantial evidence supporting the gene-disease relationship, however, data challenging the relationship is also not present, and therefore while the role in monogenic disease is not supported based on currently available evidence, the clinical relevance of these genes is not ruled out. Genes were classified as disputed when evidence was deemed insufficient and panel opinion and/or literature questioned the biological relevance of the gene in the disease. Genes classified as no known disease relationship and animal model only represent candidate genes that do not yet have sufficient human data to evaluate for a clinical classification.

**Supplemental Figure**



**Figure S1. DCM gene list filtering.** An original list of 267 genes, generated by OMIM, Gene, and GenBank database queries combined with a previously published DCM gene list<sup>3</sup>, was filtered down to a list of 51 genes indicated in humans with isolated, idiopathic DCM that proceeded through the gene curation process. CV = cardiovascular; DCM = dilated cardiomyopathy.

## Supplemental References

1. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. *Nucleic Acids Res.* 2005;33(Database issue):D514-517.
2. Benson DA, Karsch-Mizrachi I, Clark K, Lipman DJ, Ostell J, Sayers EW. GenBank. *Nucleic Acids Res.* 2012;40(Database issue):D48-53.
3. McNally EM, Mestroni L. Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. *Circ Res.* 2017;121(7):731-748.
4. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. *Circ Genom Precis Med.* 2019.
5. Whiffin N, Minikel E, Walsh R, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet Med.* 2017;19(10):1151-1158.
6. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. *Nat Rev Cardiol.* 2013;10(9):531-547.
7. Nykamp K, Anderson M, Powers M, et al. Sherlock: a comprehensive refinement of the ACMG-AMP variant classification criteria. *Genet Med.* 2017;19(10):1105-1117.

Supplemental Table 1: Gene List Filtering

ORIGINAL LIST (OMIM; GENE; GenBank)	McNally 2017 (PMID 28912180)	REMOVED GENES (ALL)	REMOVED-MT/METABOLIC/ SYNDROMIC	REMOVED- NOT IDIOPATHIC DCM (OTHER CM/CV DZ)	REMOVED - NOT IDIOPATHIC DCM (NON-CV DZ/syndrome)	REMOVED - PRECURATION	REMOVED - OTHER	FINAL LIST
<b>ABCC9</b>	<b>ABCC9</b>							<b>ABCC9</b>
ACADVL		ACADVL	ACADVL					
ACE		ACE			ACE			
<b>ACTC1</b>	<b>ACTC1</b>							<b>ACTC1</b>
<b>ACTN2</b>	<b>ACTN2</b>							<b>ACTN2</b>
ADIPOQ		ADIPOQ	ADIPOQ					
ADORA1		ADORA1			ADORA1			
ADRA2C		ADRA2C		ADRA2C				
ADRB1		ADRB1		ADRB1				
ADRB2		ADRB2			ADRB2			
	AGL	AGL	AGL					
AGT		AGT			AGT			
AGTR1		AGTR1			AGTR1			
ALMS1	ALMS1	ALMS1	ALMS1					
	ALPK3	ALPK3				ALPK3		
<b>ANKRD1</b>	<b>ANKRD1</b>							<b>ANKRD1</b>
ANOS		ANOS	ANOS					
AR		AR			AR			
<b>BAG3</b>	<b>BAG3</b>							<b>BAG3</b>
BCL2		BCL2					BCL2	
BMP4		BMP4			BMP4			
	BRAF	BRAF	BRAF					
BTNL2		BTNL2		BTNL2				
	CACNA1C	CACNA1C		CACNA1C				
CACNG8		CACNG8					CACNG8	
	CALR3	CALR3					CALR3	
CASK		CASK			CASK			
	CASQ2	CASQ2		CASQ2				
CASZ1		CASZ1					CASZ1	
	CAV3 (MURC)	CAVIN4/MURC		CAV3			REPEAT (MURC)	
CAVIN4		CD34					CD34	
CD34		CD40LG			CD40LG			
CD40LG		CD46			CD46			
CD46		CDH2	CDH2					
CDH2		CHGA					CHGA	
CHGA		CHRM2					CHRM2	
	CHRM3	CHRM3			CHRM3			
CMD1B		CMD1B					CMD1B	
CMD1H		CMD1H					CMD1H	
CMD1K		CMD1K					CMD1K	
CMD1Q		CMD1Q					CMD1Q	
	CPT2	CPT2	CPT2					
CRP		CRP					CRP	
CRYAB		CRYAB	CRYAB					
<b>CSRP3</b>	<b>CSRP3</b>							<b>CSRP3</b>
	<b>CTF1</b>							<b>CTF1</b>
CTLA4		CTLA4			CTLA4			
CTNNA3	CTNNA3	CTNNA3		CTNNA3				
CTSB		CTSB			CTSB			
CTSL		CTSL					CTSL	
CX3CR1		CX3CR1		CX3CR1				
CXADR		CXADR			CXADR			
CYP2E1		CYP2E1			CYP2E1			
DAG1		DAG1	DAG1					
<b>DES</b>	<b>DES</b>							<b>DES</b>
DMD	DMD	DMD	DMD					
DNAJC19	DNAJC19	DNAJC19	DNAJC19					
	DOLK	DOLK	DOLK					
DSC2		DSC2				DSC		
<b>DSG2</b>	<b>DSG2</b>							<b>DSG2</b>
	<b>DSP</b>							<b>DSP</b>
	<b>DTNA</b>							<b>DTNA</b>
EDN1		EDN1		EDN1				
EDNRA		EDNRA			EDNRA			
EDNRB		EDNRB			EDNRB			
	EMD	EMD	EMD					
ERBB2		ERBB2			ERBB2			
ESR1		ESR1		ESR1				
ESR2		ESR2			ESR2			

ESRRB		ESRRB		ESRRB			
<b>EYA4</b>	<b>EYA4</b>					<b>EYA4</b>	
FAS		FAS		FAS			
FBXO32		FBXO32				FBXO32	
FHOD3		FHOD3				FHOD3	
	FHL1	FHL1	FHL1				
	FHL2	FHL2	FHL2				
FKRP	FKRP	FKRP	FKRP				
FKTN	FKTN	FKTN	FKTN				
<b>FLNC</b>	<b>FLNC</b>						<b>FLNC</b>
FN1		FN1		FN1			
FOXD4		FOXD4				FOXD4	
	FRDA/FXN	FRDA/FXN	FRDA/FXN				
	GAA	GAA	GAA				
GATA4	GATA4	GATA4			GATA4		
GATA6	GATA6	GATA6			GATA6		
<b>GATAD1</b>	<b>GATAD1</b>						<b>GATAD1</b>
GBE1		GBE1	GBE1				
GDF1		GDF1	GDF1	GDF1			
GJA4		GJA4				GJA4	
	GLA	GLA	GLA				
HAND1		HAND1				HAND1	
HAVCR1		HAVCR1				HAVCR1	
	HCN4	HCN4		HCN4			
HFE	HFE	HFE		HFE			
HLA-DQB1		HLA-DQB1					
HLA-DRB1		HLA-DRB1					
HLA-DRB4		HLA-DRB4				HLA-DRB4	
HLA-G		HLA-G					
	HOPX	HOPX				HOPX	
	HRAS	HRAS	HRAS				
HSPD1		HSPD1		HSPD1			
IFIH1		IFIH1		IFIH1			
IFNG		IFNG		IFNG			
IGF1		IGF1		IGF1			
IL10		IL10		IL10			
IL17A		IL17A				IL17A	
IL17F		IL17F		IL17F			
IL1B		IL1B		IL1B			
IL2RA		IL2RA		IL2RA			
IL6		IL6		IL6			
	<b>ILK</b>						<b>ILK</b>
ITGA6		ITGA6		ITGA6			
ITGB1BP2		ITGB1BP2				ITGB1BP2	
ITGB4		ITGB4		ITGB4			
ITLN1		ITLN1				ITLN1	
ITPR2		ITPR2		ITPR2			
	<b>JPH2</b>						<b>JPH2</b>
	JUP	JUP		JUP			
KCNJ11		KCNJ11		KCNJ11			
KCNJ12		KCNJ12				KCNJ12	
KCNJ2		KCNJ2	KCNJ2				
KCNN3		KCNN3		KCNN3			
KCNQ1	KCNQ1	KCNQ1	KCNQ1				
	KRAS	KRAS	KRAS				
LAMA2	LAMA2	LAMA2	LAMA2				
<b>LAMA4</b>	<b>LAMA4</b>						<b>LAMA4</b>
LAMP2	LAMP2	LAMP2	LAMP2				
LCN2		LCN2				LCN2	
<b>LDB3</b>	<b>LDB3</b>						<b>LDB3</b>
LGALS3		LGALS3				LGALS3	
<b>LMNA</b>							<b>LMNA</b>
LRP1		LRP1		LRP1			
<b>LRRC10</b>	<b>LRRC10</b>						<b>LRRC10</b>
LRRC32		LRRC32				LRRC32	
LTBP4		LTBP4		LTBP4			
	MAP2K1	MAP2K1	MAP2K1				
	MAP2K2	MAP2K2	MAP2K2				
MAPK14		MAPK14				MAPK14	
	<b>MIB1</b>						<b>MIB1</b>
MIR199A1		MIR199A1				MIR199A1	
MIR208A		MIR208A				MIR208A	
MIR214		MIR214				MIR214	
MIR451A		MIR451A				MIR451A	
MLIP		MLIP				MLIP	



MMP1		MMP1		MMP1		
MMP10		MMP10			MMP10	
MMP14		MMP14				
MMP3		MMP3	MMP3	MMP14		
MMP7		MMP7			MMP7	
MMP9		MMP9		MMP9		
MT-TI		MT-TI				
	MTND1	MTND1	MTTI			
	MTND5	MTND5	MTND1			
	MTND6	MTND6	MTND5			
	MTTD	MTTD	MTND6			
	MTTG	MTTG	MTTD			
	MTTH	MTTH	MTTG			
	MTTI	MTTI	MTTH			
	MTTK	MTTK	MTTI			
	MTTL1	MTTL1	MTTK			
	MTTL2	MTTL2	MTTL1			
	MTTM	MTTM	MTTL2			
	MTTQ	MTTQ		MTTM		
	MTTS1	MTTS1		MTTQ		
	MTTS2	MTTS2		MTTS1		
	MURC	MURC/CAVIN		MTTS2		
CAVIN4					MURC/CAVIN	
MYBPC1		MYBPC1		MYBPC1		
<b>MYBPC3</b>	<b>MYBPC3</b>					<b>MYBPC3</b>
MYC		MYC		MYC		
<b>MYH6</b>	<b>MYH6</b>					<b>MYH6</b>
<b>MYH7</b>	<b>MYH7</b>					<b>MYH7</b>
<b>MYL2</b>	<b>MYL2</b>					<b>MYL2</b>
	<b>MYL3</b>					<b>MYL3</b>
	MYLK2	MYLK2				
MYOM1	MYOM1	MYOM1	MYLK2			
	MYO22	MYO22	MYOM1			
			MYO22			
<b>MYPN</b>						<b>MYPN</b>
NAMPT		NAMPT			NAMPT	
NDUFV1		NDUFV1		NDUFV1		
<b>NEBL</b>	<b>NEBL</b>					<b>NEBL</b>
<b>NEXN</b>	<b>NEXN</b>					<b>NEXN</b>
NFKB1	NFKB1	NFKB1		NFKB1		
	<b>NKX2-5</b>					<b>NKX2-5</b>
NLRP3		NLRP3		NLRP3		
NOS3		NOS3		NOS3		
<b>NPPA</b>	<b>NPPA</b>					<b>NPPA</b>
NPPB		NPPB			NPPB	
NPPC		NPPC		NPPC		
NPR2		NPR2		NPR2		
NR3C2		NR3C2		NR3C2		
	NRAS	NRAS	NRAS			
<b>OBSCN</b>						<b>OBSCN</b>
OSM		OSM			OSM	
PDCCD1		PDCCD1		PDCCD1		
PDE2A		PDE2A			PDE2A	
PDE3A		PDE3A		PDE3A		
	<b>PDLIM3</b>					<b>PDLIM3</b>
PGM1		PGM1	PGM1			
	<b>PKP2</b>					<b>PKP2</b>
PLEC1	PLEC1	PLEC1	PLEC			
<b>PLEKHM2</b>	<b>PLEKHM2</b>					<b>PLEKHM2</b>
<b>PLN</b>	<b>PLN</b>					<b>PLN</b>
PNPLA2		PNPLA2	PNPLA2			
POLG		POLG	POLG			
PPP1R13L		PPP1R13L			PPP1R13L	
<b>PRDM16</b>	<b>PRDM16</b>					<b>PRDM16</b>
	PRKAG2	PRKAG2		PRKAG2		
<b>PSEN1</b>						<b>PSEN1</b>
<b>PSEN2</b>						<b>PSEN2</b>
	PTPN11	PTPN11	PTPN11			
			RAF1			
RAF1	RAF1	RAF1	(Noonan/Rasopathy)			
RARRES2		RARRES2			RARRES2	
<b>RBM20</b>	<b>RBM20</b>					<b>RBM20</b>
			RIT1			
	RIT1	RIT1	(noonan/rasopathy)			
RYSR2	RYSR2	RYSR2				

<b>SCN5A</b>	<b>SCN5A</b>							<b>SCN5A</b>
SDHA	SDHA		SDHA					
SERPINE1		SERPINE1			SERPINE1			
	SGCA	SGCA	SGCA					
	SGCB	SGCB	SGCB					
<b>SGCD</b>	<b>SGCD</b>							<b>SGCD</b>
	SGCG	SGCG	SGCG					
SGK1		SGK1					SGK1	
	SLC22A5	SLC22A5	SLC22A5					
SLC25A5P8		SLC25A5P8					SLC25A5P8	
SOD2	SOD2	SOD2					SOD2	
	SOS1	SOS1	SOS1					
SPEG		SPEG	SPEG					
SRF		SRF					SRF	
STAT3		STAT3			STAT3			
SYNE1		SYNE1	SYNE3					
	SYNM	SYNM					SYNM	
TAX1BP3		TAX1BP3					TAX1BP3	
TAZ	TAZ	TAZ	TAZ					
<b>TBX20</b>	<b>TBX20</b>							<b>TBX20</b>
TBX5		TBX5			TBX5			
<b>TCAP</b>	<b>TCAP</b>							<b>TCAP</b>
TFAP2A		TFAP2A			TFAP2A			
TGFB1		TGFB1			TGFB1			
	TGFB3	TGFB3	TGFB3					
TIMP1		TIMP1					TIMP1	
TIMP4		TIMP4					TIMP4	
	TMEM43	TMEM43	TMEM43					
TMPO		TMPO					TMPO	
TNC		TNC			TNC			
TNF		TNF			TNF			
TNFRSF11B		TNFRSF11B			TNFRSF11B			
TNFRSF12A		TNFRSF12A					TNFRSF12A	
TNFSF10		TNFSF10					TITNFSF10	
TNFSF12		TNFSF12					TNFSF1	
<b>TNNC1</b>	<b>TNNC1</b>							<b>TNNC1</b>
<b>TNNI3</b>	<b>TNNI3</b>							<b>TNNI3</b>
<b>TNNI3K</b>	<b>TNNI3K</b>							<b>TNNI3K</b>
<b>TNNT2</b>	<b>TNNT2</b>							<b>TNNT2</b>
TP53		TP53			TP53			
<b>TPM1</b>	<b>TPM1</b>							<b>TPM1</b>
	TRDN	TRDN	TRDN					
TRPV2		TRPV2					TRPV2	
<b>TTN</b>	<b>TTN</b>							<b>TTN</b>
	TTR	TTR	TTR					
TWIST1		TWIST1			TWIST			
TXNRD2	TXNRD2	TXNRD2	TXNRD2					
<b>VCL</b>	<b>VCL</b>							<b>VCL</b>
VEGFA		VEGFA			VEGFA			
ZASP		ZASP					REPEAT - SEE	
ZBTB17	ZBTB17	ZBTB17					LDB3	
							ZBTB17	
<b>TOTAL: 204</b>	<b>TOTAL: 63 (125-62)</b>	<b>TOTAL: 216</b>	<b>TOTAL: -55</b>	<b>TOTAL: -26</b>	<b>TOTAL: -70</b>	<b>TOTAL: -5</b>	<b>TOTAL: -60</b>	<b>TOTAL: 51</b>
<b>TOTAL BEFORE REMOVED: 267</b>	<b>TOTAL AFTER REMOVED: 51</b>	<b>TOTAL OF ALL REMOVED CATEGORIES: 216</b>					<b>TOTAL FINAL LIST: 51</b>	

Supplemental Table 2: DCM Panel Composition

DCM Classification	Curated Genes	USA: Invitae	USA: EGL Genetic Diagnostics	USA: Prevention Genetics	USA: Cincinnati's Childrens Hospital	USA: Ambry Genetics	Finland: Blueprint Genetics	USA: Fulgent Genetics	USA: Washington University	Spain: Health in Code	USA: Knight Diagnostic Laboratories	Spain: CGC Genetics	USA: Gene Dx	Germany: CeGaT GmbH	Germany: MGZ - Medical Genetics Center	Canada: LifeLabs Genetics	USA: Sema4	Panel Totals	% Panels Present	
Definitive	BAG3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	DES	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	LMNA	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	MYH7	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	PLN	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	RBM20	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	SCN5A	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	TTN	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	TNNC1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	15	93.8%	
	TNNT2	1	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	15	93.8%	
	FLNC	1	0	1	1	1	1	1	1	1	0	1	1	1	0	0	1	12	75.0%	
																			0	0.0%
	Strong	DSP	1	1	1	1	0	1	1	0	1	1	1	1	1	1	1	1	14	87.5%
																		0	0.0%	
Moderate	ACTC1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	TNNI3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	TPM1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	VCL	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	ACTN2	0	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	15	93.8%	
	NEXN	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	15	93.8%	
	JPH2	0	0	0	1	0	1	1	0	0	0	0	0	1	0	0	0	4	25.0%	
																		0	0.0%	
Limited	ABCC9	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	LDB3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	MYBPC3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	MYH6	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	TCAP	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	16	100.0%	
	ANKRD1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	15	93.8%	
	CSRP3	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	15	93.8%	
	LAMA4	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	15	93.8%	
	MYPN	1	1	1	1	1	0	1	1	1	1	1	1	1	1	1	1	15	93.8%	
	DSG2	1	1	1	1	0	1	1	0	1	1	1	1	1	1	1	1	14	87.5%	
	GATAD1	1	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	14	87.5%	
	ILK	1	0	1	1	0	1	1	1	1	1	1	1	1	1	1	1	14	87.5%	
	NEBL	1	1	1	1	0	0	1	1	1	1	1	1	1	1	0	1	13	81.3%	
	PRDM16	1	1	1	1	0	1	1	0	1	0	1	1	1	1	1	1	13	81.3%	
	SGCD	0	1	1	1	0	0	1	1	1	1	1	1	1	1	1	1	13	81.3%	
	EYA4	1	0	1	1	0	0	1	1	1	1	1	0	0	1	1	1	11	68.8%	
	NKX2-5	1	0	1	1	1	1	1	1	1	0	1	1	0	0	0	0	10	62.5%	
	TBX20	0	0	0	1	1	1	1	1	1	0	0	1	0	1	0	1	9	56.3%	
	DTNA	0	0	0	1	0	0	1	0	0	1	0	0	1	1	0	0	5	31.3%	
	MYL2	0	0	0	1	0	0	1	0	1	0	1	0	1	0	0	0	5	31.3%	
	CTF1	1	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	4	25.0%	
	PLEKHM2	1	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	3	18.8%	
	PSEN2	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	3	18.8%	
TNNI3K	0	0	0	0	1	1	0	0	1	0	0	0	0	0	0	0	3	18.8%		
OBSCN	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	2	12.5%		
																		0	0.0%	
Disputed	PDLIM3	1	1	1	1	0	0	1	1	1	1	1	0	1	1	1	0	12	75.0%	

	PKP2	1	0	1	1	0	1	1	0	1	1	1	0	1	1	1	1	12	75.0%
	MYL3	0	0	0	1	0	0	1	0	1	0	1	0	1	0	0	0	5	31.3%
	PSEN1	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	3	18.8%
																		0	0.0%
No Known Dise	MIB1	0	0	1	1	0	0	1	0	1	0	0	1	0	0	0	0	5	31.3%
	LRRC10	1	0	0	1	0	1	0	1	0	0	0	1	0	0	0	0	5	31.3%
	NPPA	1	0	0	0	0	0	1	1	0	0	1	0	0	0	0	0	4	25.0%